Notably, (SPP1)+/− cells synergise with tumour-specific fibroblast activation protein (FAP)+ fibroblasts to establish a desmoplastic reaction, which limits the infiltration of cytotoxic T cells, thus restricting efficacy of checkpoint inhibitor therapy [65]. This evidence concerns the gene SPP1 and neoplasm.